This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q2. However, lower license and collaboration fees induce a slight dip in year-over-year revenues.
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
by Zacks Equity Research
TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.
Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
by Zacks Equity Research
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings as well as sales in the second quarter. It raises earnings expectations for 2018 but slightly lowers the sales range.
AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.
Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales.
Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
Top Analyst Reports for Johnson & Johnson, Nike & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Nike (NKE) and Schlumberger (SLB).
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress
by Swarup Gupta
The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.
Johnson & Johnson and General Motors: Growth and Income Stocks
by Brian Hamilton
This week I discuss two companies within the Income Investor portfolio; Johnson & Johnson (JNJ) and General Motors (GM).
Interpublic's Weber Shandwick Acquires Social Agency That Lot
by Zacks Equity Research
Interpublic's (IPG) Weber Shandwick acquires That Lot to boost its multi-platform capabilities and expand client base globally.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Healthcare ETFs in Focus Following JNJ Q2 Results
by Sweta Killa
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
Stock Market News For Jul 18, 2018
by Zacks Equity Research
Markets closed sharply higher on Tuesday, led by a rally in tech stocks.
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
by Ryan McQueeney
Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.
J&J's (JNJ) Phase III Study for Invokana Halted Earlier
by Zacks Equity Research
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
These Companies are Earnings All-Stars
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
Watch Out For Goldman
by Zacks Equity Research
Watch Out For Goldman